Subcutaneous certolizumab pegol is effective in anti-TNF naive patients and patients with prior infliximab use - Hanauer,S.B.; Colombel,J.F.; Sandborn,W.J.; Panes,J.; McColm,J.A.; Schreiber,S. (Am J Gastroenterol, 2006)